Efficacy of Topical Compound Danxiong Granules for Treatment of Dermatologic Toxicities Induced by Targeted Anticancer Therapy: A Randomized, Double-Blind, Placebo-Controlled Trial
Table 2
Baseline patient characteristics.
Characteristic
Compound Danxiong Granules ()
Placebo ()
value
Mean age/range (years)
55 (31–72)
53 (33–70)
0.478
Sex
0.841
Male
44 (65.7%)
21 (63.6%)
Female
23 (24.3%)
12 (26.4%)
Type of tumor
0.992
Hepatocarcinoma
12 (17.9%)
5 (15.2%)
Renal carcinoma
10 (14.9%)
6 (18.2%)
Lung cancer
22 (32.8%)
11 (33.3%)
Intestinal cancer
21 (31.3%)
10 (30.3%)
Breast cancer
1 (1.5%)
1 (3.0%)
Soft tissue sarcoma
1 (1.5%)
Targeted anticancer agents
0.997
Sorafenib
14 (20.9%)
6 (18.2%)
Sunitinib
8 (11.9%)
5 (15.2%)
Erlotinib
12 (17.9%)
6 (18.2%)
Gefitinib
10 (14.9%)
5 (15.2%)
Cetuximab
21 (31.3%)
10 (30.3%)
Famitinib
2 (3.0%)
1 (3.0%)
Type of skin lesions
0.994
Hand-foot skin reaction
22 (32.8%)
11 (33.3%)
Acneiform eruption
26 (38.8%)
13 (39.4%)
Paronychia
19 (28.9%)
9 (27.3%)
Severity of skin lesions
0.134
Grade I
5 (7.5%)
6 (18.2%)
Grade II
28 (41.8%)
16 (48.5%)
Grade III
34 (50.7%)
11 (33.3%)
Time after the initiation of targeted anticancer therapies
